Upstate Active Clinical Trials

Study Title:

A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL

Upstate Institutional Review Board (IRB) Number:

1335388

Study/Protocol ID:

A041501

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Jeffrey J Pu

Where will the study take place?

SUNY Upstate Medical University
University Physicians at Oneida (Consent Only)
University Physicians at Oswego (Consent Only)

ClinicalTrials.Gov ID:

NCT03150693

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Corey Chase
Phone: 315-464-4187
Email: chasec@upstate.edu

Return to Previous Page || Search Again

Top